Market Place
Sourcing Support
OKYO Pharma Chief Development Officer And Director Acquire Shares
19 Mar 2026 //
GLOBENEWSWIRE
OKYO Pharma Announces Director Acquires Shares
19 Mar 2026 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman And Founder Acquires Shares
19 Mar 2026 //
GLOBENEWSWIRE
OKYO Pharma Announces Public Offering Of Ordinary Shares
12 Feb 2026 //
GLOBENEWSWIRE
OKYO Pharma Shifts Equity Offering Facility To Leerink Partners
11 Feb 2026 //
GLOBENEWSWIRE
OKYO Pharma Names Flavio Mantelli As Chief Medical Officer
10 Feb 2026 //
GLOBENEWSWIRE
OKYO Pharma Announces Successful Type C Meeting With The FDA
28 Jan 2026 //
GLOBENEWSWIRE
FDA Approves Urcosimod 0.05% to Treat Neuropathic Corneal Pain
23 Jan 2026 //
GLOBENEWSWIRE
OKYO Pharma Names Robert J. Dempsey as CEO
05 Jan 2026 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman And Founder Acquires Shares
15 Dec 2025 //
GLOBENEWSWIRE
Okoyo Pharma Reports Positive Corneal Nerve Results
11 Dec 2025 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman And Founder Acquires Shares
03 Dec 2025 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman And Founder Acquires Shares
21 Nov 2025 //
GLOBENEWSWIRE
OKYO Pharma To Present At OIS XV In San Diego
18 Nov 2025 //
GLOBENEWSWIRE
OKYO Pharma To Present At Bio-Europe 2025 In Vienna
29 Oct 2025 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman And Founder Acquires Shares
16 Oct 2025 //
GLOBENEWSWIRE
Okoyo Pharma Initiates 100-Patient Trial For Urcosimod
22 Sep 2025 //
GLOBENEWSWIRE
OKYO Pharma Gets $1.9M to Advance Urcosimod for Eye Pain
17 Jul 2025 //
GLOBENEWSWIRE
OKYO Pharma to Present at the Bio International Convention
11 Jun 2025 //
GLOBENEWSWIRE
Okyo Pharma to Present at GPCRs-Targeted Drug Discovery Summit
19 May 2025 //
GLOBENEWSWIRE
Okyo Pharma to Accelerate Clinical Development of Urcosimod
30 Apr 2025 //
GLOBENEWSWIRE
OKYO Pharma Reports Positive Long-Term Urcosimod Stability
31 Mar 2025 //
GLOBENEWSWIRE
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
12 Feb 2025 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman and CEO Acquire Shares
31 Jan 2025 //
GLOBENEWSWIRE
OKYO to Complete Enrollment of Neuropathic Corneal Pain Trial
29 Jan 2025 //
GLOBENEWSWIRE
Okyo Pharma Receives $1.4 Million in Non-Dilutive Funding
22 Jan 2025 //
GLOBENEWSWIRE
OKYO Pharma to Participate at 4th Annual BTIG Ophthalmology Conf
26 Nov 2024 //
GLOBENEWSWIRE
OKYO Pharma to Present at Tear Film & Ocular Surface Society
30 Oct 2024 //
GLOBENEWSWIRE
OKYO Pharma Doses First Patient in Neuropathic Pain Trial
23 Oct 2024 //
GLOBENEWSWIRE
Okyo Pharma Starts Phase 2 Trial For Neuropathic Corneal Pain
16 Oct 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman Acquires Shares
10 Sep 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman Acquires Shares
05 Sep 2024 //
GLOBENEWSWIRE
OKYO Pharma Granted US Patent For OK-101 In Dry Eye Disease Treatment
27 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman Acquires Shares
23 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma CEO Interview to Air on Bloomberg TV
23 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman Acquires Shares
21 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma Joins H.C. Wainwright Ophthalmology Virtual Conference
15 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma Granted European Patent For OK-101 Chemerin Analogs
06 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
11 Jul 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Participation in May 2024 Investor Conferences
08 May 2024 //
GLOBENEWSWIRE
OKYO to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
08 Apr 2024 //
GLOBENEWSWIRE
OKYO to Discuss New and Comprehensive Data from Ph 2 Dry Eye Disease Trial
21 Mar 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Ophthalmologists with Expertise in the Medical Treatment
31 Jan 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
31 Oct 2023 //
GLOBENEWSWIRE
OKYO Announces Closing of $4.0 Million Registered Direct Offering of Shares
15 Sep 2023 //
GLOBENEWSWIRE
OKYO Pharma Limited Announces Withdrawal of Public Offering
14 Sep 2023 //
GLOBENEWSWIRE
OKYO Announces Pricing of $4.0 Million Registered Direct Offering of Shares
14 Sep 2023 //
GLOBENEWSWIRE
OKYO Pharma Regains Compliance with Nasdaq Listing Minimum Market Value Rule
29 Aug 2023 //
GLOBENEWSWIRE
OKYO Pharma Reports Annual Results for the Twelve Months Ended March 31, 2023
15 Aug 2023 //
GLOBENEWSWIRE
Okyo withdraws offer to sell shares after just 3 days
31 Jul 2023 //
FIERCE BIOTECH
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
28 Jul 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
28 Jul 2023 //
GLOBENEWSWIRE
OKYO Announces Appointment of William A. Clementi as Chief Operating Officer
27 Jul 2023 //
GLOBENEWSWIRE
OKYO Pharma Participating on Webull Corporate Communications Service Platform
11 May 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces Presentations at (ASCRS 2023) in San Diego, CA
03 May 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces Activation of First Clinical Trial SiteU.S. for the Ph2
25 Apr 2023 //
GLOBENEWSWIRE
OKYO Pharma Management Takes Company Stock In Private Placement
18 Apr 2023 //
ACCESSWIRE
Notice of General Meeting and Publication of Circular
05 Apr 2023 //
GLOBENEWSWIRE
OKYO Pharma Today Announces Director Acquires Shares
30 Mar 2023 //
GLOBENEWSWIRE
OKYO Pharma Today Announces Director Acquires Shares
29 Mar 2023 //
GLOBENEWSWIRE
